RxDoctor Payments DataLook up a doctor →

Cassandra Curtis, MD

Neurology · Indianapolis, INNPI 1093808917

Payments from drug & device makers

$188,892in general payments, 2019–2025

Across 628 payments — averaging $300.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$106K
  • Biohaven Pharmaceuticals, Inc.$28K
  • Biohaven Pharmaceutical Holding Company Ltd.$16K
  • Promius Pharma LLC$15K
  • Astrazeneca UK Limited$8K
  • Genentech USA, Inc.$7K
  • plus $9K from 45 others

What the payments were for

  • Consulting fees$7,0344%
  • Speaking & faculty fees$157,67587%
  • Travel & lodging$4,1652%
  • Food & beverage$11,9287%
  • Education$900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$188,892 in reported general payments places this provider in the 90th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$96,458
Medicare patients
415
Services billed
1,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5021$121,018
MysolinePrimidone13$75,111
KeppraLevetiracetam18$45,755
Depakote ErDivalproex Sodium17$30,575
Aimovig AutoinjectorErenumab-Aooe13$15,153
Nurtec OdtRimegepant Sulfate12$11,680
Emgality PenGalcanezumab-Gnlm16$10,973
Memantine Hcl223$8,840
Gabapentin200$6,569
Pregabalin91$5,114
Levetiracetam96$4,427
Propranolol Hcl ErPropranolol Hcl70$3,908
Primidone145$2,812
Oxcarbazepine22$2,372
Carbidopa-LevodopaCarbidopa/Levodopa116$2,371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$24$121,01821 claims
PfizerNurtec Odt$208$11,68012 claims
Upsher-smith Laboratories LLCTopiramate$54$95057 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 neurology providers in Indiana.

Other neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →